TABLE 2.
Characteristics and timing to onset of alopecia areata after COVID‐19 infection and vaccination
| Individuals who had COVID‐19 infection (n = 59) | 59/131 (45.0%) |
| Symptoms of AA after COVID‐19 infection (n = 25) | 25/59 (42.4%) |
| New onset diagnosis of AA | 15/25 (60.0%) |
| Relapse of pre‐existing AA | 9/25 (36.0%) |
| Declined to specify | 1/25 (4.0%) |
| Timing of AA symptoms, where specified (n = 22) | |
| Mean (SD) days to onset of AA symptoms | 50.6 (31.7) |
| Individuals who had COVID‐19 vaccination (n = 113) | 113/131 (86.3%) |
| Symptoms of AA after COVID‐19 vaccination (n = 77) | 77/113 (68.1%) |
| New onset diagnosis of AA | 39/77 (50.6%) |
| Relapse of pre‐existing AA | 38/77 (49.4%) |
| Manufacturer of first COVID‐19 vaccination (n = 113) | |
| Pfizer | 65/113 (57.0%) |
| Moderna | 22/113 (19.3%) |
| AstraZeneca | 13/113 (11.4%) |
| Johnson & Johnson | 8/113 (7.0%) |
| Sinovac | 1/113 (0.9%) |
| Other/Declined to specify | 4/113 (3.5%) |
| Timing of AA symptoms, where reported (n = 47) | |
| Mean (SD) days to onset of AA symptoms | 61.5 (72.7) |
| After first COVID‐19 vaccination | 12/47 (25.5%) |
| After second COVID‐19 vaccination | 25/47 (53.2%) |
| After third COVID‐19 vaccination | 10/47 (21.3%) |
Abbreviations: AAA, alopecia areata; SD, standard deviation.